In particular, the fully human monoclonal antibody dupilumab behaves as a dual IL-4/IL-13 receptor antagonist, which according to both randomized trials and real-life studies has been shown to effectively inhibit type-2 inflammation, thus significantly improving several clinical and functional parameters related to asthma (Figure 1), nasal polyposis, and atopic dermatitis (Pelaia et al., 2017; Ricciardolo et al., 2021). Here, IL4 is linked to asthma.